Consistent with published data in pathology showing present yet intermediate expression of PSMA in the tumor neovasculature of non-clear cell RCC subtypes, only a small portion of sites of non-clear cell RCC were shown to take up the PSMA-targeting radiotracer 18F-DCFPyL, indicating that PSMA-based PET/CT imaging is likely not appropriate for imaging of these tumors. This evidence concerns the gene FOLH1 and neoplasm.